



FIRST-QUARTER 2023 RESULTS

TOTAL COMPANY

\$9.7B

SALES
WORLDWIDE

10%

Organic* sales growth for
underlying base business**

\$1.03²

ADJUSTED DILUTED EPS

CONTINUE TO FORECAST

\$4.30 to \$4.50³

FULL-YEAR 2023 ADJUSTED DILUTED EPS

Reflects increased outlook for underlying base business
offset by lower forecasted earnings contribution
from COVID-19 testing-related sales

BUSINESS UNIT SALES



\$3.9B

MEDICAL DEVICES



\$2.7B

DIAGNOSTICS



\$1.2B

ESTABLISHED
PHARMACEUTICALS



\$2.0B

NUTRITION

BUSINESS HIGHLIGHTS

HELPING PEOPLE WITH DIABETES WHO USE INSULIN

- ▶ FDA clearance for FreeStyle Libre[®] 2 and FreeStyle Libre[®] 3 sensors for integration with automated insulin delivery (AID) systems
- ▶ AID systems automatically adjust and administer the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors



CARDIOVASCULAR LEADERSHIP

- ▶ New data show superiority of TriClip[®] device compared to medical therapy for tricuspid regurgitation, with significant improvement in quality of life
- ▶ Announced agreement to acquire Cardiovascular Systems, Inc. (CSI), which would add to our leading vascular device offerings

INNOVATION IN CHRONIC PAIN TREATMENT

- ▶ FDA approval of new indication for Proclaim[®] XR Spinal Cord Stimulation System to treat painful diabetic peripheral neuropathy
- ▶ System is able to use NeuroSphere[™] Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely



*Organic sales growth excludes impact of foreign exchange, as well as the impact of exiting the pediatric nutrition business in China. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 19, 2023, available at www.abbottinvestor.com.

**Excludes the impact of COVID-19 testing sales.

***Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

1. On a GAAP basis, first-quarter 2023 Abbott sales decreased 18.1%. 2. First-quarter GAAP diluted EPS was \$0.75. 3. Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of \$3.05 to \$3.25. Abbott forecasts specified items for the full-year 2023 of \$1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be \$4.30 to \$4.50 for the full-year 2023.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.